Market Closed -
Japan Exchange
11:30:00 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
3,255
JPY
|
+0.90%
|
|
+3.96%
|
-34.85%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,42,875
|
5,71,160
|
5,54,319
|
5,61,052
|
3,92,668
|
2,19,233
|
-
|
-
|
Enterprise Value (EV)
1 |
5,00,737
|
5,24,046
|
4,93,520
|
5,03,199
|
3,23,731
|
2,35,236
|
1,47,374
|
1,32,557
|
P/E ratio
|
33.3
x
|
33.9
x
|
26.8
x
|
22.5
x
|
17.2
x
|
11.6
x
|
8.62
x
|
8.05
x
|
Yield
|
0.87%
|
1.01%
|
1.2%
|
1.32%
|
1.96%
|
2.77%
|
3.89%
|
3.98%
|
Capitalization / Revenue
|
4.73
x
|
4.9
x
|
4.55
x
|
4.08
x
|
2.72
x
|
2.03
x
|
1.44
x
|
1.37
x
|
EV / Revenue
|
4.37
x
|
4.49
x
|
4.05
x
|
3.66
x
|
2.25
x
|
1.59
x
|
0.97
x
|
0.83
x
|
EV / EBITDA
|
20.8
x
|
20.8
x
|
16.6
x
|
16.1
x
|
9.23
x
|
6.14
x
|
3.87
x
|
3.25
x
|
EV / FCF
|
35.6
x
|
51.2
x
|
26.2
x
|
52.1
x
|
37.9
x
|
36.9
x
|
6.8
x
|
5.9
x
|
FCF Yield
|
2.81%
|
1.95%
|
3.81%
|
1.92%
|
2.64%
|
2.71%
|
14.7%
|
17%
|
Price to Book
|
4.02
x
|
3.93
x
|
3.42
x
|
3.11
x
|
2.01
x
|
1.37
x
|
0.92
x
|
0.86
x
|
Nbr of stocks (in thousands)
|
67,354
|
67,354
|
67,353
|
67,353
|
67,353
|
67,353
|
-
|
-
|
Reference price
2 |
8,060
|
8,480
|
8,230
|
8,330
|
5,830
|
3,255
|
3,255
|
3,255
|
Announcement Date
|
13/05/19
|
13/05/20
|
14/05/21
|
11/05/22
|
11/05/23
|
10/05/24
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,14,716
|
1,16,637
|
1,21,885
|
1,37,484
|
1,44,175
|
1,48,255
|
1,52,243
|
1,59,480
|
EBITDA
1 |
24,062
|
25,136
|
29,684
|
31,232
|
35,090
|
38,318
|
38,104
|
40,809
|
EBIT
1 |
20,644
|
21,668
|
26,134
|
32,948
|
30,049
|
33,295
|
32,550
|
35,159
|
Operating Margin
|
18%
|
18.58%
|
21.44%
|
23.96%
|
20.84%
|
22.46%
|
21.38%
|
22.05%
|
Earnings before Tax (EBT)
1 |
21,540
|
22,442
|
28,759
|
33,301
|
30,489
|
33,616
|
32,950
|
35,538
|
Net income
1 |
16,302
|
16,866
|
20,702
|
24,986
|
22,812
|
25,851
|
25,626
|
27,218
|
Net margin
|
14.21%
|
14.46%
|
16.98%
|
18.17%
|
15.82%
|
17.44%
|
16.83%
|
17.07%
|
EPS
2 |
242.0
|
250.4
|
307.4
|
371.0
|
338.7
|
383.8
|
377.6
|
404.1
|
Free Cash Flow
1 |
14,068
|
10,237
|
18,805
|
9,659
|
8,539
|
6,368
|
21,658
|
22,483
|
FCF margin
|
12.26%
|
8.78%
|
15.43%
|
7.03%
|
5.92%
|
4.3%
|
14.23%
|
14.1%
|
FCF Conversion (EBITDA)
|
58.47%
|
40.73%
|
63.35%
|
30.93%
|
24.33%
|
16.62%
|
56.84%
|
55.09%
|
FCF Conversion (Net income)
|
86.3%
|
60.7%
|
90.84%
|
38.66%
|
37.43%
|
24.63%
|
84.51%
|
82.6%
|
Dividend per Share
2 |
70.00
|
86.00
|
99.00
|
110.0
|
114.0
|
124.0
|
126.6
|
129.4
|
Announcement Date
|
13/05/19
|
13/05/20
|
14/05/21
|
11/05/22
|
11/05/23
|
10/05/24
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2020 S2
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 S1
|
2025 Q3
|
2025 Q4
|
2026 S1
|
---|
Net sales
1 |
57,387
|
59,250
|
57,817
|
30,411
|
71,568
|
34,650
|
31,329
|
35,619
|
71,136
|
38,783
|
34,256
|
37,012
|
36,302
|
73,314
|
39,414
|
35,527
|
37,423
|
37,150
|
74,500
|
39,000
|
37,715
|
80,000
|
EBITDA
1 |
-
|
-
|
-
|
5,792
|
-
|
8,568
|
-293
|
-
|
-
|
10,117
|
3,424
|
-
|
-
|
-
|
10,805
|
4,173
|
8,715
|
6,785
|
-
|
11,300
|
9,100
|
-
|
EBIT
1 |
11,025
|
10,643
|
11,140
|
5,056
|
21,504
|
7,817
|
-1,022
|
10,276
|
19,161
|
8,826
|
2,062
|
11,163
|
9,715
|
20,878
|
9,572
|
2,845
|
7,962
|
7,342
|
14,000
|
9,550
|
6,465
|
17,000
|
Operating Margin
|
19.21%
|
17.96%
|
19.27%
|
16.63%
|
30.05%
|
22.56%
|
-3.26%
|
28.85%
|
26.94%
|
22.76%
|
6.02%
|
30.16%
|
26.76%
|
28.48%
|
24.29%
|
8.01%
|
21.27%
|
19.76%
|
18.79%
|
24.49%
|
17.14%
|
21.25%
|
Earnings before Tax (EBT)
1 |
11,271
|
11,171
|
11,248
|
5,652
|
22,250
|
8,313
|
-790
|
10,514
|
19,398
|
9,024
|
2,067
|
11,440
|
9,706
|
21,146
|
9,827
|
2,643
|
8,105
|
7,472
|
14,200
|
9,710
|
6,585
|
17,200
|
Net income
1 |
8,291
|
8,575
|
8,073
|
4,220
|
16,561
|
6,045
|
438
|
8,249
|
15,222
|
7,452
|
138
|
8,749
|
-
|
16,176
|
7,826
|
1,849
|
6,205
|
5,722
|
10,900
|
7,460
|
5,535
|
12,800
|
Net margin
|
14.45%
|
14.47%
|
13.96%
|
13.88%
|
23.14%
|
17.45%
|
1.4%
|
23.16%
|
21.4%
|
19.21%
|
0.4%
|
23.64%
|
-
|
22.06%
|
19.86%
|
5.2%
|
16.58%
|
15.4%
|
14.63%
|
19.13%
|
14.68%
|
16%
|
EPS
2 |
123.1
|
-
|
119.9
|
62.65
|
245.9
|
89.75
|
6.500
|
122.5
|
226.0
|
110.6
|
2.050
|
129.9
|
-
|
240.2
|
116.2
|
27.45
|
91.96
|
96.80
|
161.8
|
96.80
|
66.37
|
190.0
|
Dividend per Share
2 |
43.00
|
-
|
49.00
|
-
|
51.00
|
-
|
-
|
-
|
57.00
|
-
|
-
|
-
|
62.00
|
62.00
|
-
|
62.00
|
-
|
65.00
|
-
|
-
|
65.00
|
-
|
Announcement Date
|
06/11/19
|
13/05/20
|
05/11/20
|
10/11/21
|
10/11/21
|
10/02/22
|
11/05/22
|
09/08/22
|
10/11/22
|
10/02/23
|
11/05/23
|
10/08/23
|
13/11/23
|
13/11/23
|
09/02/24
|
10/05/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
42,138
|
47,114
|
60,799
|
57,853
|
68,937
|
65,831
|
71,859
|
86,676
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
14,068
|
10,237
|
18,805
|
9,659
|
8,539
|
6,368
|
21,658
|
22,483
|
ROE (net income / shareholders' equity)
|
12.5%
|
12%
|
13.5%
|
13.6%
|
12.1%
|
12.4%
|
11.2%
|
11.3%
|
ROA (Net income/ Total Assets)
|
13.2%
|
13.1%
|
14.4%
|
16%
|
9.97%
|
10.3%
|
10.3%
|
9.95%
|
Assets
1 |
1,23,724
|
1,29,182
|
1,43,910
|
1,56,428
|
2,28,696
|
2,50,429
|
2,48,050
|
2,73,555
|
Book Value Per Share
2 |
2,003
|
2,160
|
2,409
|
2,681
|
2,904
|
3,270
|
3,528
|
3,793
|
Cash Flow per Share
2 |
293.0
|
302.0
|
360.0
|
439.0
|
414.0
|
458.0
|
474.0
|
474.0
|
Capex
1 |
1,242
|
2,500
|
2,583
|
10,744
|
5,660
|
16,430
|
7,325
|
7,888
|
Capex / Sales
|
1.08%
|
2.14%
|
2.12%
|
7.81%
|
3.93%
|
11.08%
|
4.81%
|
4.95%
|
Announcement Date
|
13/05/19
|
13/05/20
|
14/05/21
|
11/05/22
|
11/05/23
|
10/05/24
|
-
|
-
|
Last Close Price
3,255
JPY Average target price
3,987
JPY Spread / Average Target +22.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -34.85% | 1.36B | | +55.32% | 815B | | +44.05% | 641B | | -6.75% | 352B | | +13.56% | 314B | | +10.68% | 303B | | +16.57% | 242B | | +13.31% | 218B | | +8.48% | 168B | | -2.81% | 159B |
Other Pharmaceuticals
|